Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23605988 | 0.85 | L3MBTL1 (0.49) | ALDH1A1LMNAPPARGPPARAMAPT | |
| SCHEMBL21992534 | 0.84 | PPARA (0.61) | ALDH1A1NPSR1LMNAMAPK1TDP1 | |
| SCHEMBL21991270 | 0.84 | PPARA (0.43) | LDHAALDH1A1NPSR1LMNAMAPK1 | |
| SCHEMBL21992541 | 0.84 | PPARA (0.41) | PPARGPPARAMAPTKDM4E | |
| SCHEMBL21991504 | 0.84 | ALDH1A1 (0.46) | CA1CA2CES2CES1ALDH1A1 | |
| SCHEMBL21992551 | 0.81 | PPARA (0.47) | ALDH1A1PPARGPPARA | |
| SCHEMBL21991844 | 0.80 | PPARA (0.56) | ALDH1A1PPARGPPARAMAPT | |
| SCHEMBL21991487 | 0.80 | CYP1A2 (0.45) | ALDH1A1ALOX15HSD17B10PPARGPPARA | |
| SCHEMBL7236788 | 0.79 | ALDH1A1 (0.49) | CA1CA2PDE4BLDHAALDH1A1 | |
| SCHEMBL21991505 | 0.78 | CYP1A2 (0.46) | LDHACES2CES1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CA1 4372/4885CA2 4634/4885PDE4B 139/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | CA1 4372/4885CA2 4634/4885PDE4B 139/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CA1 4372/4885CA2 4634/4885PDE4B 139/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | CA1 4372/4885CA2 4634/4885PDE4B 139/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | CA1 4372/4885CA2 4634/4885PDE4B 139/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CA1 4372/4885CA2 4634/4885PDE4B 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.